background: Eprotirome is a liver selective thyroid hormone receptor agonist that effectively lowered plasma low-density lipoprotein cholesterol (LDL-C) levels in previous phase I and II studies. We set out to assess the long-term safety and efficacy of 50 and 100 µg eprotirome in patients with familial hypercholesterolemia (FH). The study was prematurely terminated because of the concurrent recognition of cartilage damage in canines. methods: Although it was impossible to meet the predefined study outcomes, we analyzed the changes in lipid levels, liver parameters, thyroid hormone levels and adverse effects after treatment with eprotirome or placebo after the initial 6 weeks of therapy.
